Tarsus Pharmaceuticals, Inc. Common Stock TARS
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T00:56:47.957Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:02.948724448Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T00:56:47.586755+00:00
Tarsus Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 108.46 | 218.5% | 44.6% | 63.99 | 163.4% | 19.9% |
| 25Δ | 93.66 | 158.5% | 25.3% | 68.51 | 127.4% | 14.0% |
| 30Δ | 86.58 | 122.0% | 16.1% | 71.41 | 104.3% | 10.3% |
| 35Δ | 73.35 | 92.6% | 8.1% | |||
| 40Δ | 79.85 | 78.0% | 7.3% | 74.92 | 86.2% | 6.6% |
| 45Δ | 78.53 | 72.3% | 5.9% | 76.12 | 79.5% | 5.4% |
| 50Δ | 77.30 | 66.8% | 4.6% | 77.31 | 72.7% | 4.2% |
| 55Δ | 76.39 | 62.3% | 3.8% | 78.40 | 70.7% | 3.5% |
| 60Δ | 75.47 | 57.8% | 2.9% | 79.47 | 69.6% | 2.9% |
| 65Δ | 74.41 | 58.1% | 2.3% | 80.68 | 69.8% | 2.3% |
| 70Δ | 73.18 | 63.7% | 2.1% | 82.04 | 71.3% | 1.9% |
| 75Δ | 72.16 | 64.5% | 1.7% | 83.35 | 70.5% | 1.5% |
| 80Δ | 71.40 | 59.2% | 1.3% | 84.63 | 68.5% | 1.1% |
20Δ
- Pseudo strike
- 108.46
- IV
- 218.5%
- B/E move
- 44.6%
- Pseudo strike
- 63.99
- IV
- 163.4%
- B/E move
- 19.9%
25Δ
- Pseudo strike
- 93.66
- IV
- 158.5%
- B/E move
- 25.3%
- Pseudo strike
- 68.51
- IV
- 127.4%
- B/E move
- 14.0%
30Δ
- Pseudo strike
- 86.58
- IV
- 122.0%
- B/E move
- 16.1%
- Pseudo strike
- 71.41
- IV
- 104.3%
- B/E move
- 10.3%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 73.35
- IV
- 92.6%
- B/E move
- 8.1%
40Δ
- Pseudo strike
- 79.85
- IV
- 78.0%
- B/E move
- 7.3%
- Pseudo strike
- 74.92
- IV
- 86.2%
- B/E move
- 6.6%
45Δ
- Pseudo strike
- 78.53
- IV
- 72.3%
- B/E move
- 5.9%
- Pseudo strike
- 76.12
- IV
- 79.5%
- B/E move
- 5.4%
50Δ
- Pseudo strike
- 77.30
- IV
- 66.8%
- B/E move
- 4.6%
- Pseudo strike
- 77.31
- IV
- 72.7%
- B/E move
- 4.2%
55Δ
- Pseudo strike
- 76.39
- IV
- 62.3%
- B/E move
- 3.8%
- Pseudo strike
- 78.40
- IV
- 70.7%
- B/E move
- 3.5%
60Δ
- Pseudo strike
- 75.47
- IV
- 57.8%
- B/E move
- 2.9%
- Pseudo strike
- 79.47
- IV
- 69.6%
- B/E move
- 2.9%
65Δ
- Pseudo strike
- 74.41
- IV
- 58.1%
- B/E move
- 2.3%
- Pseudo strike
- 80.68
- IV
- 69.8%
- B/E move
- 2.3%
70Δ
- Pseudo strike
- 73.18
- IV
- 63.7%
- B/E move
- 2.1%
- Pseudo strike
- 82.04
- IV
- 71.3%
- B/E move
- 1.9%
75Δ
- Pseudo strike
- 72.16
- IV
- 64.5%
- B/E move
- 1.7%
- Pseudo strike
- 83.35
- IV
- 70.5%
- B/E move
- 1.5%
80Δ
- Pseudo strike
- 71.40
- IV
- 59.2%
- B/E move
- 1.3%
- Pseudo strike
- 84.63
- IV
- 68.5%
- B/E move
- 1.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 62.26% | |
| 62.87% | |
| 63.02% | |
| 64.15% | |
| 65.34% | |
| 66.42% | |
| 66.00% | |
| 66.80% | |
| 66.76% | |
| 69.65% |
Biotechnology
TECH
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is…
More →TECX
Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel therapies for patients…
More →TENX
Tenax Therapeutics, Inc., a specialty pharmaceutical company, is dedicated to identifying, developing, and marketing products for cardiovascular and pulmonary disease in the…
More →TGTX
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and…
More →TNGX
Description unavailable
More →TNXP
Tonix Pharmaceuticals Holding Corp. The company is headquartered in Chatham, New Jersey.
More →